The Sage Group: 30 Years of Successful Bioscience TransactionsLondon and New York, September 1 2024 - The Sage Group ( www.sagehealthcare.com ), a leading global advisor in the bioscience sector,...
Coagulant’s CT-001 - An Opportunity To License A Novel Factor VIIa with Orphan Drug Designation for the Treatment of Severe Postpartum Hemorrhage (sPPH)Our client, Coagulant Therapeutics Corporation (CTC), is developing a novel, patented (4 families due to expire 2041-2043 period)...
Partnering/Licensing Opportunity for Tecarfarin, a Phase 3-Ready Oral Anticoagulant for Patients with Certain Orphan DiseasesCadrenal Therapeutics ( www.cadrenal.com ; NASDAQ: CVKD) is a public U.S. company focused on advancing the development and...
